Co-Diagnostics Price to Book Ratio

Co-Diagnostics posts a P/B ratio of 0.09. That is above the Healthcare sector average of -49.54. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a P/B ratio near -49.54 is typical. Co-Diagnostics's 0.09 is higher that level. That is roughly 100.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Co-Diagnostics's P/B ratio of 0.09 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for CODX's P/B ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -49.54), and (3) consistency with growth and profitability. This page covers the first two; Co-Diagnostics's other metric pages and overview cover the third.

Judging Co-Diagnostics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in P/B ratio easier to interpret. Start with 0.09 here, then scan peer and history charts to see if the gap is persistent.